Explore and discuss estetrol and other natural estrogens in combined oral contraceptives in relation to cardiovascular outcomes.
This session will focus on:
- What is estetrol and how it differs from other estrogens in COCs
- How recent studies have helped us better understand the impact of COCs on haemostasis
- What cardiovascular risk studies reveal about COCs containing natural versus synthetic estrogens, and whether clinical trials show meaningful differences
A panel discussion for 20 minutes with local experts exploring the impact on current practice will follow.
Speakers:
Mitchell D. Creinin, MD | Distinguished Professor, Director of Complex Family Planning Fellowship, Department of Obstetrics and Gynecology, University of California Davis Health
The growth blueprint: setting your practice up for success
Speakers:
Aston Chee | Special Counsel (Commercial & Corporate), Avant Law
Jack Wald | Relationship Director (Commercial Finance), Avant Finance
